PrecivityAD2 is a blood test to help diagnose Alzheimer's disease in adults age 40 and older with cognitive symptoms. In 2026, primary care patients can access it only with a clinician order, at a $1,450 list price with new Anthem coverage for eligible members, plus clear follow-up questions. Younger-onset evaluation means symptoms starting during working years, when diagnosis affects jobs, families, and care plans. Primary care is often the first visit, so knowing access rules, costs, and next steps helps patients use the appointment well.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does the test measure?
- Who can receive it in primary care?
- How much does it cost?
- What follow-up questions should you ask?
What does the test measure?
PrecivityAD2 measures two blood ratios linked to Alzheimer's brain changes. According to NeurologyLive, it uses high-resolution mass spectrometry to measure plasma amyloid-beta 42/40 plus p-tau217/non-p-tau217 ratios in its validation and test details report.
Results combine into an Amyloid Probability Score 2 of negative, positive, or likely positive. In C2N Diagnostics' 1,142-patient validation against amyloid PET or spinal fluid tests, positive results had 97.6% positive predictive value. Negative results had 93.1% negative predictive value, supporting both rule-in and rule-out use in symptomatic patients.
Who can receive it in primary care?
According to C2N Diagnostics, the Food and Drug Administration cleared PrecivityAD2 on Aug. 20, 2026 as the first Alzheimer's blood test for symptomatic adults age 40 and older in the FDA clearance announcement. That age threshold matters for younger-onset concerns because two prior cleared tests had higher age limits.
The test is available in all 50 states plus Washington, D.C. only when ordered by a health care professional. It is not a direct-consumer purchase or walk-in screening test, so patients need symptoms, a clinician visit, and a test order.
How much does it cost?
The list price is $1,450, and coverage has historically been limited. Patients should ask the clinic about current out-of-pocket cost, billing codes, and financial-assistance eligibility before blood is drawn.
According to C2N Diagnostics, starting Oct. 1, 2026, eligible Anthem Blue Cross and Blue Shield members receive medical-policy coverage for PrecivityAD2 evaluation in the coverage announcement. Anthem members should ask whether they meet eligibility rules and whether prior authorization is required.
What follow-up questions should you ask?
About 17.3% of validation patients received an intermediate likely positive result with only 77.3% positive predictive value. Patients should ask: does my score need confirmatory PET or spinal fluid testing, and where would that occur? According to the Alzheimer's Association, FDA labeling requires use alongside clinical assessment by clinicians experienced in cognitive impairment in its FDA clearance summary. Patients should ask what history, exam, labs, and other causes will be reviewed, and whether neurology, neuropsychology, or social-work referral is next.
You Might Also Like
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: Access, Cost, and Follow-Up Questions for Primary Care Patients
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: Access, Cost, and Follow-Up Questions for Primary Care Patients
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: Access, Cost, and Follow-Up Questions for Primary Care Patients
